Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest announcement is out from SAB Biotherapeutics (SABS).
SAB Biotherapeutics has successfully completed the third cohort dosing in phase one trials for their new drug, SAB-142, without any cases of serum sickness reported. The company plans to release a detailed corporate update mid-April, which could be a significant point of interest for investors and followers of the biotech industry.
For an in-depth examination of SABS stock, go to TipRanks’ Stock Analysis page.
